XML 30 R21.htm IDEA: XBRL DOCUMENT
v3.23.1

Co-Development Agreement with Life Technologies Corporation | 3 Months Ended
--- | ---
Mar. 31, 2023
Co-development Agreement With Life Technologies Corporation |
Co-Development Agreement with Life Technologies Corporation | 14. Co-Development Agreement with Life Technologies Corporation On January 13, 2022, Oncocyte entered into a Collaboration Agreement (the “LTC Agreement”) with Life Technologies Corporation, a Delaware corporation and subsidiary of Thermo Fisher Scientific (“LTC” and together with Oncocyte, the “Parties” or individually, a “Party”), in order to partner in the development and collaborate in the commercialization of Thermo Fisher Scientific’s existing Oncomine Comprehensive Assay Plus (“OCA Plus”) and Oncocyte’s DetermaIO assay for use with LTC’s Ion TorrentTM GenexusTM Integrated Sequencer and LTC’s Ion TorrentTM GenexusTM Purification System (“Genexus system”) in order to obtain in vitro diagnostic (“IVD”) regulatory approval. On February 7, 2023, Oncocyte entered into a Termination Agreement (the “Termination Agreement”) with LTC, pursuant to which the parties terminated the LTC Agreement. ONCOCYTE CORPORATION NOTES TO CONSOLIDATED FINANCIAL STATEMENTS As of March 31, 2023, Oncocyte was responsible for reimbursing LTC for $749,000 of certain development costs under the terms of the LTC Agreement.

X
- Definition Co development agreementwith life technologies corporation [TextBlock] + References No definition available. + Details
Name: | OCX_CoDevelopmentAgreementwithLifeTechnologiesCorporationTextBlock
Namespace Prefix: | OCX_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | OCX_DisclosureCodevelopmentAgreementWithLifeTechnologiesCorporationAbstract
Namespace Prefix: | OCX_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration